Christopher Ogden - Sep 26, 2025 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role: Chief Financial Officer
Signature: /s/ Christopher Ogden
Stock symbol: CTMX
Transactions as of: Sep 26, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/30/2025, 06:38 PM
Previous filing: Jun 17, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Ogden Christopher	Chief Financial Officer	C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO	/s/ Christopher Ogden	2025-09-30	0001914523

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTMX	Stock Option (Right to Buy)	Award	$0	+78.3K		$0.00	78.3K	Sep 26, 2025	Common Stock	78.3K	$2.90	Direct	F1
transaction	CTMX	Performance Stock Units (PSUs)	Award	$0	+39.2K		$0.00	39.2K	Sep 26, 2025	Common Stock	39.2K		Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
F2	Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.